ATLANTA, USA, (CDC News) – US Centers for Disease Control and Prevention (CDC) Director Mandy Cohen recommends second dose of 2024-2025 COVID-19 vaccine for people 65 years and older and for people who are moderately or severely immunocompromised and has endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation for lowering the age for pneumococcal vaccination from 65 to 50 years old.
CDC Advisory Committee on Immunization Practices’ (ACIP)
Lowering the age for pneumococcal vaccination gives more adults the opportunity to protect themselves from pneumococcal disease at the age when risk of infection substantially increases. Pneumococcal bacteria can cause serious illnesses, including pneumonia, meningitis, and bloodstream infections, and older adults are at increased risk for pneumococcal disease.
Adults 50 years or older should talk with a healthcare provider to make sure they’re up to date with pneumococcal vaccination. Now is a great time to get vaccinated against pneumococcal disease in preparation for the winter respiratory season.
For more information on pneumococcal disease, visit.
CDC recommends second dose of 2024-2025 COVID-19
CDC drector Cohen endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation for people 65 years and older and those who are moderately or severely immunocompromised to receive a second dose of 2024-2025 COVID-19 vaccine six months after their first dose. These updated recommendations also allow for flexibility for additional doses (i.e., three or more) for those who are moderately or severely immunocompromised, in consultation with their healthcare provider (a strategy known as shared clinical decision making).
The recommendation acknowledges the increased risk of severe disease from COVID-19 in older adults and those who are immunocompromised, along with the currently available data on vaccine effectiveness and year-round circulation of COVID-19. The recommendation also provides clarity to healthcare providers on how many doses should be given per year to people who are moderately or severely immunocompromised and is meant to increase coverage of this second dose for that group.
Data continues to confirm the importance of vaccination to protect those most at risk for severe outcomes of COVID-19. Receiving recommended 2024-2025 COVID-19 vaccines can restore and enhance protection against the virus variants currently responsible for most infections and hospitalizations in the United States. COVID-19 vaccination also reduces the chance of suffering the effects of Long COVID, which can develop during or following acute infection and last for an extended duration.
CDC and ACIP will continue to monitor COVID-19 vaccine safety and effectiveness. CDC continues to recommend that everyone stay up to date on their COVID-19 vaccines, especially people ages 65 years and older and those with weakened immune systems.
For more information on updated COVID-19 vaccines visit.
The following statement is attributable to CDC director Dr Mandy Cohen:
“This vote allows people to make the best decisions possible to keep themselves and their loved ones safe from COVID-19. CDC will continue to educate the public on how and when to get their updated vaccinations so they can risk less severe illness and do more of what they love.”
The post CDC recommends lowering the age for Pneumococcal vaccination from 65 to 50 years old: Second dose of 2024-2025 COVID-19 vaccine for people 65 years and older and for people who are moderately or severely immunocompromised appeared first on Caribbean News Global.
